EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma

Manouk K Bos iD, Jaco Kraan, Martijn P A Starmans, Jean C A Helmijr, Noortje Verschoor iD, Maja J A De Jonge, Arjen Joosse, Astrid A M van der Veldt, Peter A W Te Boekhorst, John W M Martens iD, Stefan Sleijfer, Saskia M Wilting

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Manouk K Bos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Melanoma, Circulating Tumor DNA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society, KWF kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in therapeutic approaches for melanoma urge the need for biomarkers that can identify patients at risk for recurrence and to guide treatment. The potential use of liquid biopsies in identifying biomarkers is increasingly being recognized. Here, we present a head‐to‐head comparison of several techniques to analyze circulating tumor cells (CTCs) and cell‐free DNA (cfDNA) in 20 patients with metastatic melanoma. In this study, we investigated whether diagnostic leukapheresis (DLA) combined with multimarker flow cytometry (FCM) increased the detection of CTCs in blood compared to the CellSearch platform. Additionally, we characterized cfDNA at the level of somatic mutations, extent of aneuploidy and genome‐wide DNA methylation. Both CTCs and cfDNA measures were compared to tumor markers and extracranial tumor burden on radiological imaging. Compared to the CellSearch method applied on peripheral blood, DLA combined with FCM increased the proportion of patients with detectable CTCs from 35% to 70% ( P = 0.06). However, the median percentage of cells that could be recovered by the DLA procedure was 29%. Alternatively, cfDNA mutation and methylation analysis detected tumor load in the majority of patients (90% and 93% of samples successfully analyzed, respectively). The aneuploidy score was positive in 35% of all patients. From all tumor measurements in blood, lactate dehydrogenase (LDH) levels were significantly correlated to variant allele frequency ( P = 0.004). Furthermore, the presence of CTCs in DLA was associated with tumor burden ( P < 0.001), whereas the presence of CTCs in peripheral blood was associated with number of lesions on radiological imaging ( P < 0.001). In conclusion, DLA tended to increase the proportion of patients with detectable CTCs but was also associated with low recovery. Both cfDNA and CTCs were correlated with clinical parameters such as LDH levels and extracranial tumor burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingMelanomaCirculating Tumor DNAHumansFemaleMaleMiddle AgedAgedNeoplasm MetastasisBiomarkers, TumorAdultMutationDNA MethylationCell-Free Nucleic AcidsAged, 80 and overAneuploidyLiquid Biopsy

Stichwörter der Autor:innen

circulating tumor DNAcirculating tumor cellsliquid biopsymelanoma

Substanzen

Circulating Tumor DNABiomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Manouk K Bos, Noortje Verschoor, John W M Martens

Förderung

  • Dutch Cancer Society
  • KWF kankerbestrijding

Zitieren

APA

Bos, M. K., Kraan, J., Starmans, M. P. A., Helmijr, J. C. A., Verschoor, N., De Jonge, M. J. A., Joosse, A., van der Veldt, A. A. M., Te Boekhorst, P. A. W., Martens, J. W. M., Sleijfer, S., & Wilting, S. M. (2024). Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13650

Vancouver

Bos MK, Kraan J, Starmans MPA, Helmijr JCA, Verschoor N, De Jonge MJA, et al. Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma. Molecular Oncology. 2024. doi:10.1002/1878-0261.13650

BibTeX
@article{Bos2024,
  author = {Bos, Manouk K and Kraan, Jaco and Starmans, Martijn P A and Helmijr, Jean C A and Verschoor, Noortje and De Jonge, Maja J A and Joosse, Arjen and van der Veldt, Astrid A M and Te Boekhorst, Peter A W and Martens, John W M and Sleijfer, Stefan and Wilting, Saskia M},
  title = {Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13650}
}
Kostenlos starten →